Chemotherapy of advanced ovarian  carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.
Twenty-four fully staged, previously untreated patients with advanced ovarian carcinoma were prospectively randomized to either intensive intravenous cyclophosphamide or conventional oral Melphalan therapy. The median durations of initial remissions (5 and 6 mo) and the median durations of survival (15 and 14 mo) were similar for the two regimens but the toxicity of the intensive regimen was excessive. Followup indicates that long term disease free survivals are possible in those patients who achieve complete remissions on chemotherapy alone as three of the four patients achieving complete remission in the present study remain free of disease with a median survival in excess of 30 mo. High dose intensive alkylating agent therapy in the manner used in the present study fails to enhance the response to chemotherapy and produces unacceptable toxicity.
D000230:Adenocarcinoma / Q000188:drug therapy*; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy*; D000284:Administration, Oral; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D003536:Cystadenocarcinoma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D010535:Laparoscopy; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D012075:Remission, Spontaneous; D014481:United States
D003520:Cyclophosphamide; D008558:Melphalan